Nxera Pharma
Mariko Nakafuji currently serves as the General Counsel at Nxera Pharma since May 2021, where notable achievements include facilitating the Sosei Group's up-listing to the Tokyo Stock Exchange Prime Market and overseeing significant capital issuances. Prior to this role, Mariko held the position of Head of UK Legal and Compliance at Deloitte UK from June 2016 to May 2021, and practiced as Corporate Legal Counsel at JONES DAY® between September 2014 and May 2016, specializing in private equity and M&A transactions. Earlier career experiences include roles as Corporate Finance Associate and Trainee Solicitor at Berwin Leighton Paisner, along with paralegal positions in various law firms. Mariko's educational background includes studies at The London School of Economics and Political Science, Seisen International School, and The College of Law.
This person is not in any teams
This person is not in any offices
Nxera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery “NxWave” platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).